Joseph B. Guttenplan

Prof. Joseph B. Guttenplan

1. Department of Basic Science, New York University College of Dentistry, New York, NY 10010, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

59Years (1968-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2006 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
ECErcole Cavalieri
Ercole Cavalieri
DCDhubajyoti Chakravarti
Dhubajyoti Chakravarti
Joseph B. GuttenplanJoseph B. Guttenplan
Joseph B. Guttenplan
EHElizabeth Hart
Elizabeth Hart
JIJames Ingle
James Ingle
TSThomas Sutter
Thomas Sutter

1 May 1984 in Kidney International
Verified
Journal Article
Closed access
RSRobert Safirstein
Robert Safirstein
PMPeter Miller
Peter Miller
Joseph B. GuttenplanJoseph B. Guttenplan
Joseph B. Guttenplan

1 November 1986 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
RSRobert Safirstein
Robert Safirstein
JWJonathan Winston
Jonathan Winston
MGMarvin Goldstein
Marvin Goldstein
DMDonald Moel
Donald Moel
SDSteven Dikman
Steven Dikman
Joseph B. GuttenplanJoseph B. Guttenplan
Joseph B. Guttenplan
Cis-dichlorodiammine platinum (II), or cisplatin, has emerged as a principal chemotherapeutic agent in the treatment of otherwise resistant solid tumors and is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy is its nephrotoxicity, which has made it necessary both to lower its dosage and actively hydrate patients to reduce it. The vulnerability of the kidney to cisplatin is almost certainly related to its primary role in the excretion of cisplatin. Cisplatin enters renal cells by a process that depends on normal oxygen utilization and is specifically inhibited by organic bases. Greater localization of platinum to the S3 segment of the proximal tubules suggests that the vulnerability of this segment may depend on its specific uptake of the drug. The majority of intracellular platinum is bound to macromolecules, including protein and DNA, yet a significant portion of cell platinum is biotransformed to a nonmutagenic and possibly nontoxic compound. Polyuria and hypomagnesemia, which are commonly associated with cisplatin nephrotoxicity, may be due to defects in deep nephron or collecting duct fluid and solute transport. Low single nephron glomerular filtration rates (SNGFR) during early cisplatinum-induced acute renal failure is accompanied by reduced renal blood flow and transglomerular hydrostatic pressure without elevated intratubular hydrostatic pressure, suggesting preglomerular vasoconstriction as an important determinant of renal failure.(ABSTRACT TRUNCATED AT 250 WORDS)

1 February 1987 in International Journal of Andrology
Verified
Journal Article
Open access
PDF file
RSR. Safirstein
R. Safirstein
JWJ. Winston
J. Winston
DMD. Moel
D. Moel
SDS. Dikman
S. Dikman
Joseph B. GuttenplanJoseph B. Guttenplan
Joseph B. Guttenplan
Cis‐dichlorodiammine platinum (II), or cisplatin, is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy is its nephrotoxicity. Acute and chronic nephrotoxicity of cisplatin occurs in man and animals especially after repeated administration. Morphological damage is restricted to the P3 segment of the proximal tubule. Abnormalities of water and solute reclamation and transglomerular passage of fluid are commonly associated with cisplatin nephrotoxicity. The vulnerability of the kidney to cisplatin may be related to its function as the primary excretory organ for platinum. Platinum binds to multiple cellular organelles and macromolecules, yet the precise mechanism of its cytotoxicity has not been delineated. Because abnormalities in renal function are preceded by a period where gross renal function appears normal, it is an ideal model to study the early physiological and biochemical determinants of metal induced acute renal failure.

1 May 1972 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
Joseph B. GuttenplanJoseph B. Guttenplan
Joseph B. Guttenplan
SCSaul G. Cohen
Saul G. Cohen

1 September 1987 in Mutation Research/Reviews in Genetic Toxicology
Verified
Journal Article
Closed access
Joseph B. GuttenplanJoseph B. Guttenplan
Joseph B. Guttenplan